COMPANY
MalarVx
MalarVx Inc. is a biopharmaceutical company focused on developing a malaria vaccine. From company website Source · checked 2026-10-19
Sources for this description (1)
- MalarVx Inc. is a biopharmaceutical company focused on developing a malaria vaccine.
- “MalarVx Inc. is a biopharmaceutical company focused on developing an effective malaria vaccine.” https://malarvx.com/about/ (2026-10-19)
NIH awards 2
- NIH award 5R43AI149889-02 FY2021: $217,162 awarded for that fiscal year; activity R43 (SBIR); PI AVRIL, MARION; recipient as written: MALARVX, INC., SEATTLE, WA. Biological Equivalence of In Vitro Plasmodium falcipar source ↗
- NIH award 1R43AI149889-01 FY2020: $230,288 awarded for that fiscal year; activity R43 (SBIR); PI AVRIL, MARION; recipient as written: MALARVX, INC., SEATTLE, WA. Biological Equivalence of In Vitro Plasmodium falcipar source ↗
Funding and NIH signals
- SEC Form D raise Raised $125K (Form D filed Aug 25, 2026). SEC Form D 0001559688-26-000003 (Aug 25, 2026)
Evidence (1 event)
- Aug 25, 2026 · SEC Form D 0001559688-26-000003
Name of Issuer: MalarVx, Inc.; CIK: 1559688; Address: Seattle, WA; Submission type: D; Filing date: 2026-08-25; Industry Group: Biotechnology; Date of First Sale: 2026-08-08; Types of Securities Offered: Other (Promissory Note convertible into equity.); Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 125000; Federal exemptions: 06b
- Aug 25, 2026 · SEC Form D 0001559688-26-000003